fluconazole and incb-018424

fluconazole has been researched along with incb-018424 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Allada, G; Sullivan, DR; Wysham, NG	1
Fraczkiewicz, G; Shi, JG; Williams, WV; Yeleswaram, S	1
Aslanis, V; Bharathy, S; Butler, AA; Gadbaw, B; Huth, F; Ouatas, T; Umehara, K; Zhou, W	1

Trials

1 trial(s) available for fluconazole and incb-018424

Article	Year
Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects. Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:4 Topics: Adult; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Female; Fluconazole; Half-Life; Healthy Volunteers; Humans; Janus Kinases; Male; Metabolic Clearance Rate; Middle Aged; Nitriles; Pyrazoles; Pyrimidines; Signal Transduction	2019

Article

Year

Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects.

Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:4

Topics: Adult; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Female; Fluconazole; Half-Life; Healthy Volunteers; Humans; Janus Kinases; Male; Metabolic Clearance Rate; Middle Aged; Nitriles; Pyrazoles; Pyrimidines; Signal Transduction

2019

Other Studies

2 other study(ies) available for fluconazole and incb-018424

Article	Year
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest, 2013, Volume: 143, Issue:5 Topics: Aged; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Enzyme Inhibitors; Fluconazole; Humans; Immunity, Cellular; Janus Kinase 1; Janus Kinase 2; Lung; Male; Nitriles; Opportunistic Infections; Pneumonia, Bacterial; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome	2013
Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib. Clinical pharmacology and therapeutics, 2015, Volume: 97, Issue:2 Topics: Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Drug Interactions; Erythromycin; Fasting; Fluconazole; Humans; Ketoconazole; Models, Biological; Nitriles; Prospective Studies; Pyrazoles; Pyrimidines; Retrospective Studies; Rifampin	2015

Article

Year

An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.

Chest, 2013, Volume: 143, Issue:5

Topics: Aged; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Enzyme Inhibitors; Fluconazole; Humans; Immunity, Cellular; Janus Kinase 1; Janus Kinase 2; Lung; Male; Nitriles; Opportunistic Infections; Pneumonia, Bacterial; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome

2013

Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib.

Clinical pharmacology and therapeutics, 2015, Volume: 97, Issue:2

Topics: Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Drug Interactions; Erythromycin; Fasting; Fluconazole; Humans; Ketoconazole; Models, Biological; Nitriles; Prospective Studies; Pyrazoles; Pyrimidines; Retrospective Studies; Rifampin

2015